Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open Label, Phase I Study to Assess and Compare the Pharmacokinetic Parameters After Single Oral Administration of Elafibranor 120 mg in Renal Impaired Patients and Healthy Subjects With Normal Renal Function

Next Previous
Search
Trial Profile

Open Label, Phase I Study to Assess and Compare the Pharmacokinetic Parameters After Single Oral Administration of Elafibranor 120 mg in Renal Impaired Patients and Healthy Subjects With Normal Renal Function

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 14 Aug 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elafibranor (Primary)
  • Indications Liver disorders; Non-alcoholic steatohepatitis; Primary biliary cirrhosis
  • Focus Pharmacokinetics
  • Sponsors Genfit

    • Most Recent Events

    • 12 Aug 2020 Status changed from recruiting to completed.
    • 04 Feb 2020 Planned End Date changed from 1 Dec 2019 to 1 Apr 2020.
    • 04 Feb 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Apr 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top